Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-monthly islatravir for HIV-1 pre-exposure prophylaxis in MSM and transgender women
jRCT2031200419Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of islatravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoints: Adverse events and Adverse events leading to discontinuation of study intervention. Started May 2021; status: completed.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on jRCT2031200419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200419.